Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma

NCT00441818 is registered in ClinicalTrials.gov with Tanox as lead sponsor.

NCT NCT00441818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00441818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma
Lead sponsor
Tanox
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2006
Completion date
June 30, 2007
Enrollment
59 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's lymphoma